Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction

Acta Neurol Belg. 2001 Mar;101(1):39-41.

Abstract

In an open-label study 41 patients suffering from the muscular form of temporo-mandibular dysfunction were treated with botulinum toxin type A injections into masticatory muscles (average of 200 U on each side) and followed for an average of 6.7 months. Eighty percent of patients improved by a mean reduction of 45% on a visual analogue pain scale. During the observation period, 17% of patients had to receive a second injection because of recurrent pain. Reversible speech and swallowing difficulties occurred in only 1 patient. These encouraging results need to be confirmed by a randomized controlled trial.

Publication types

  • Clinical Trial

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / adverse effects
  • Facial Pain / drug therapy*
  • Facial Pain / etiology*
  • Humans
  • Masticatory Muscles
  • Neuromuscular Agents / administration & dosage*
  • Neuromuscular Agents / adverse effects
  • Pain Measurement
  • Temporomandibular Joint Disorders / complications*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A